Essity Q1 margins rise on volume growth and acquisition gains

Essity delivered improved underlying Q1 performance, with organic sales up 0.4%, EBITA margin excluding IAC rising 40 bps to 13.9%, and gross margin expanding 70 bps to 33.5% on lower raw material costs. Currency translation cut reported net sales 5.1% to SEK 33.18 billion, but constant-currency EBITA rose 5% and operating cash flow increased 16% to SEK 4.35 billion. The acquisition of Edgewell's feminine care business added SEK 370 million in revenue, and the board approved a new SEK 3 billion buyback program.

Analysis

This print is more important for margin durability than for headline growth. In a category where pricing power is usually the first casualty of weak consumer demand, the combination of mix resilience, lower input costs, and working-capital release suggests Essity is entering the year with operating leverage that can persist even if reported top-line remains noisy from FX. The market should focus on the gap between reported EPS and cash generation: that spread can fund buybacks and deleveraging simultaneously, which typically supports valuation multiples even without strong nominal revenue growth.

The new feminine care asset looks strategically better than the headline purchase price implies because it deepens a North America franchise where scale matters for retailer shelf positioning, promo efficiency, and procurement. The second-order effect is pressure on smaller branded competitors and private label in feminine care, as a better-capitalized incumbent can defend shelf space with fewer margin concessions than before. That said, the transaction also raises integration and post-close synergy execution risk over the next 2-3 quarters; any slip in volumes or margin accretion would show up first in Personal Care before it is visible at the group level.

The weak spot is Consumer Tissue, where Europe remains structurally exposed to price deflation and fragile consumer trade-down. If pulp, energy, and freight remain benign, management can mask this with mix and buybacks; if any of those inputs re-accelerate, the margin expansion story becomes much less linear. FX is the other key swing factor: with reported sales already materially distorted, the stock can still outperform operationally while the reported P&L stays capped for several months, which often creates a window for patient buyers before consensus fully resets.

Key Decisions for Investors

• Long ESSITYb on 1-3 month horizon on pullbacks: the combination of margin expansion, buyback authorization, and sub-1.0x net debt/EBITDA creates asymmetric downside protection; target a re-rating if the market starts capitalizing constant-currency EBITA rather than reported sales.
• Pair trade: long ESSITYb / short a weaker European consumer tissue or packaging name with higher input-cost sensitivity over the next 2 quarters; the relative edge is lower raw-material leverage plus stronger capital returns.
• Buy upside call spreads in ESSITYb into the next 6-9 weeks: the near-term catalyst is consensus upgrades on margin and FCF, while the buyback restart after May 11 can tighten supply and support a second leg higher.
• Avoid chasing the stock if EUR/SEK or USD/SEK reverses sharply against the company’s translation profile; FX can cap reported growth for several months even if underlying operations stay healthy.
• Watch Personal Care as the key tell: if that segment sustains mid-single-digit organic growth with margin expansion into next quarter, add to longs; if integration costs or promo intensity rise, reduce exposure ahead of the summer trading window.